Interaction Between Inflammaging and Common Cardiovascular Diseases: Current Knowledge and Treatment
Year: 2026
Type: article
Abstract: Inflammation plays a key role in the pathogenesis of major cardiovascular diseases such as hypertension, atherosclerosis, and heart failure. Chronic immune activation leads to endothelial dysfunction, contributing to increased oxidative stress, and abnormal neurohormonal responses. In patients with hypertension, vascular constriction, increased stiffness, and vascular wall remodeling occur, and activation of the renin–angiotensin–aldosterone system (RAAS) intensifies the inflammatory response through the action of angiotensin II, which stimulates the production of reactive oxygen species and inflammatory mediators. In patients with atherosclerosis, oxidized LDL activates endothelial cells and attracts monocytes, which migrate to the vessel wall and differentiate into macrophages. As the disease progresses, further activation of the immune system occurs, along with the secretion of proinflammatory cytokines (including IL‐1β, IL‐6, and TNF‐α), and proliferation of smooth muscle cells, leading to the formation of atherosclerotic plaque. In the case of heart failure, the role of the NLRP3 inflammasome is crucial, as it activates IL‐1β and intensifies the inflammatory response in the myocardium, contributing to the progression of heart failure. Progress in understanding immunological mechanisms has led to the development of modern therapeutic strategies aimed at addressing the inflammatory process. In addition to classic pleiotropic drugs such as statins and ACE inhibitors, targeted therapies are gaining increasing importance, including interleukin‐1 inhibitors (e.g., canakinumab), colchicine, and IL‐6 inhibitors, which have been shown to reduce cardiovascular risk regardless of lipid levels. Integration of modern anti‐inflammatory therapies with standard treatment opens up new possibilities for improving patient prognosis and personalizing therapy.
Source: Comprehensive physiology
DOI: 10.1002/cph4.70288
Authors: Anna Tylutka(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft), Łukasz Walas(Formal analysis, Writing – original draft), Paweł Muszyński(Formal analysis, Methodology, Writing – original draft), Katarzyna Koleśnik(Formal analysis, Methodology, Writing – original draft), Jarosław Hiczkiewicz(Writing – original draft), Agnieszka Zembron‐Lacny(Writing – original draft)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: inflammaging, cardiovascular disease, hypertension, atherosclerosis, heart failure, endothelial dysfunction, oxidative stress, renin-angiotensin-aldosterone system, angiotensin II, oxidized LDL, macrophage infiltration, inflammatory cytokines, NLRP3 inflammasome, IL-1β, IL-6 inhibitors, colchicine, canakinumab, statins, ACE inhibitors, anti-inflammatory therapy
Open Access status: hybrid
OpenAlex ID: W7236753901
